Her2 Low-Expressing Disease

The FDA granted priority review to fam-trastuzumab deruxtecan-nxki for treatment of certain patients with HER2-low breast cancer.

In this video, Kevin Kalinsky, MD, discussed new data on antibody-drug conjugates, including sacituzumab, presented at 39th Miami Breast Cancer Conference.

HER2–low expression was linked to inferior progression-free survival among breast cancer patients with estrogen receptor-positive, HER2-negative metastatic disease treated with CDK4/6 inhibitors, according to research presented at ASCO 2021.